Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines

Abstract

Scleroderma (systemic sclerosis) is an autoimmune connective tissue disease which presents endothelial dysfunction and fibroblast dysregulation, resulting in vascular and fibrotic disorders. Pulmonary hypertension is frequent in patients with systemic sclerosis: the natural evolution of the disease can induce the development of different forms of pulmonary hypertension, representing one of the main causes of death. Among the different forms of pulmonary hypertension in systemic sclerosis, pulmonary arterial hypertension is the most frequent one (rate of occurrence is estimated between 7% and 12%). This pulmonary vascular complication should be treated with a combination of drugs that is able to counteract endothelial dysfunction, antagonizing the endothelin-1 system and replacing prostaglandin I₂ and nitric oxide activity. A correct diagnosis is mandatory, because it is possible only for pulmonary arterial hypertension to use specific drugs that are able to control the symptomatic condition and the evolution of the disease. According to the most recent guidelines, for the patients with systemic sclerosis, also without pulmonary hypertension symptoms, echocardiography screening for the detection of pulmonary hypertension is recommended. Pulmonary arterial hypertension screening programs in systemic sclerosis patients is able to identify milder forms of the disease, allowing earlier management and better long-term outcome.

Keywords

Systemic sclerosis pulmonary hypertension pulmonary arterial hypertension diagnosis treatment

Get full access to this article

View all access options for this article.

References

Fishman

AP.

Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385–391.

Galiè

Simonneau

The fifth world symposium on pulmonary hypertension. J Am Coll Cardiol 2013; 62: D1–D3.

Simonneau

Gatzoulis

Adatia

et al . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: 34–41.

Denton

Khanna

Systemic sclerosis. Lancet 2017; 390: 1685–1699.

McLaughlin

Archer

Badesch

et al . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.

Coghlan

Denton

Grünig

et al . Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340–1349.

Galie

Humbert

Vachieryc

et al . 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 1855–1856.

Bae

Saggar

Bolster

et al . Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335–1342.

Stewart

Levy

Cernacek

et al . Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464–469.

10.

Giordano

Montella

Corallo

et al . Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients. Clin Exp Rheumatol 2015; 33: 182–189.

11.

Hachulla

Gressin

Guillevin

et al . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792–3800.

12.

Mukerjee

St George

Coleiro

et al . Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088–1093.

13.

Humbert

Sitbon

Chaouat

et al . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.

14.

Tyndall

Bannert

Vonk

et al . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809–1815.

15.

Humbert

Yaici

de Groote

et al . Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522–3530.

16.

Vachièry

Adir

Barberà

et al . Pulmonary hypertension due to left heart disease. J Am Coll Cardiol 2013; 24(25 Suppl.): 62.

17.

Naeije

Vachiery

Yerly

et al . The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41: 217–223.

18.

Magne

Lancellotti

Piérard

LA.

Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation 2010; 122: 33–41.

19.

Mathai

Hassoun

PM.

Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012; 8: 413–425.

20.

Seeger

Adir

Barberà

et al . Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: 109–116.

21.

Pope

Lee

Baron

et al . Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 1273–1278.

22.

McGoon

Benza

Escribano-Subias

et al . Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: 51–59.

23.

Conolly

Abdullah

Riduit

et al . Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Rheumatology 2017; 56: 2197–2203.

24.

Daraban

Enache

Predescu

et al . Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature. Rom J Intern Med 2015; 53: 175–183.

25.

Le Goullec

Duhamel

Perez

et al . Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS ONE 2017; 12(8): e0181692.

26.

Kim

Delcroix

Jenkins

et al . Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: 92–99.

27.

Vachiéry

Coghlan

Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162–169

28.

Schwaiger

Khanna

Gerry Coghlan

Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev 2013; 22: 515–525.

29.

Launay

Sitbon

Hachulla

et al . Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940–1946.

30.

Boucly

Weatherald

Savale

et al . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1–10.

31.

Said

Anticoagulation in pulmonary arterial hypertension: contemporary data from COMPERA registry. Glob Cardiol Sci Pract 2014; 18: 48–52.

32.

Wharton

Strange

Møller

et al . Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105–113.

33.

Tantini

Manes

Fiumana

et al . Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131–138.

34.

Vachiery

Huez

Gillies

et al . Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 2011; 71: 289–292.

35.

Galiè

Brundage

Ghofrani

et al . Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.

36.

Galiè

Corris

Frost

et al . Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: 60–71.

37.

Giaid

Saleh

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214–221.

38.

Jones

Benjamin

Linseman

DA.

Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48: 890–896.

39.

Christman

McPherson

Newman

et al . An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–75.

40.

Galiè

Manes

Branzi

Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2: 123–137.

41.

Rubin

Mendoza

Hood

et al . Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485–491.

42.

Badesch

Tapson

McGoon

et al . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425–434.

43.

Chin

Badesch

Robbins

et al . Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J 2014; 167(2): 218–225.

44.

Sitbon

Channick

Chin

et al . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533.

45.

Giaid

Yanagisawa

Langleben

et al . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732–1739.

46.

Galié

Manes

Branzi

The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227–237.

47.

Nadeau

Potus

Boucherat

et al . Dual ET_A/ET_B blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulm Circ. Epub ahead of print 24 October 2018. DOI: 10.1177/2045893217741429

48.

Khanna

Gladue

Channick

et al . Recommendation for screening and detection of connective tissue disease-associate pulmonary arterial hypertension. Arthritis Rheum 2013; 65: 3194–3201.

49.

McLaughlin

Gaine

Howard

et al . Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D73–D81.

50.

McLaughlin

Channick

Ghofrani

et al . Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46(2): 405–413.

51.

Hoeper

McLaughlin

Barberá

et al . Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med 2016; 4(11): 894–901.

52.

Pulido

Adzerikho

Channick

et al . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369(9): 809–818.

53.

Simonneau

Channick

Delcroix

et al . Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J 2015; 46(6): 1711–1720.

54.

Shirai

Yasuoka

Takeuchi

et al . Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. Mod Rheumatol 2013; 23(6): 1211–1220.

55.

Coghlan

Channick

Chin

et al . Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled. Am J Cardiovasc Drugs 2018; 18(1): 37–47.

56.

Actelion. The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (TRITON). ClinicalTrials.gov identifier NCT02558231, 2017, https://clinicaltrials.gov/ct2/show/NCT02558231